Patients fulfilling all of the following inclusion criteria may be enrolled in the study | |
---|---|
Inclusion criteria: | |
· Histologically or cytologically confirmed and documented malignant pleural mesothelioma with pleural effusion, | |
· Male and Female patients 18 years to 75 years of age, | |
· Signed Informed Consent after being informed, | |
· Patients medically and/or functionally at screening not accessible for surgical treatment with planned third cycle of palliative chemotherapy in 21 days, | |
· Bone marrow function: hemoglobin ≥ 100 g/L; white blood cell count (WBC) ≥ 3.0 x 109/L; absolute neutrophile count (ANC) ≥ 1.5 x 109/L; platelet count ≥ 100 x 109/L, | |
· Hepatic: aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times upper limit of normal (ULN)); bilirubin ≤ 1.5 x ULN, | |
· Renal: creatinine ≤ 2 mg/dL and creatinine clearance ≥ 45 mL/min, | |
· No concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents, | |
· The patient has received no major organ allograft, | |
· HIV-negative, | |
· HBV and HCV negative, | |
· No uncontrolled bleeding disorder, | |
· Patients of child-producing potential must agree to use contraception while enrolled in the study and for 24 months after the adoptive transfer. |